These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

434 related articles for article (PubMed ID: 35426547)

  • 1. mRNA vaccines: the most recent clinical applications of synthetic mRNA.
    Kwon S; Kwon M; Im S; Lee K; Lee H
    Arch Pharm Res; 2022 Apr; 45(4):245-262. PubMed ID: 35426547
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Rapid Development and Early Success of Covid 19 Vaccines Have Raised Hopes for Accelerating the Cancer Treatment Mechanism.
    Amanpour S
    Arch Razi Inst; 2021 Mar; 76(1):1-6. PubMed ID: 33818952
    [TBL] [Abstract][Full Text] [Related]  

  • 3. mRNA vaccines for infectious diseases: principles, delivery and clinical translation.
    Chaudhary N; Weissman D; Whitehead KA
    Nat Rev Drug Discov; 2021 Nov; 20(11):817-838. PubMed ID: 34433919
    [TBL] [Abstract][Full Text] [Related]  

  • 4. mRNA based vaccines provide broad protection against different SARS-CoV-2 variants of concern.
    Wang H; Chen Z; Wang Z; Li J; Yan Z; Yuan J; Zhu A; Chen L; Liu Y; Hu C; Zhu A; Li G; Li Y; Deng J; Ma L; Sui X; Miao W; Li J; Zheng X; Piao J; Yao Y; Rao J; Shan C; Yuan Z; Zhao J; Zhu T
    Emerg Microbes Infect; 2022 Dec; 11(1):1550-1553. PubMed ID: 35604772
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Vaccine development based on RNA technology platforms].
    Guo X; Li J; Wang HM; Qiu J; Li Z; Huang F; Li J; Sun XD
    Zhonghua Yu Fang Yi Xue Za Zhi; 2024 Aug; 58(8):1263-1277. PubMed ID: 39142899
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Demystifying mRNA vaccines: an emerging platform at the forefront of cryptic diseases.
    Rouf NZ; Biswas S; Tarannum N; Oishee LM; Muna MM
    RNA Biol; 2022; 19(1):386-410. PubMed ID: 35354425
    [TBL] [Abstract][Full Text] [Related]  

  • 7. mRNA Vaccines: The Dawn of a New Era of Cancer Immunotherapy.
    Deng Z; Tian Y; Song J; An G; Yang P
    Front Immunol; 2022; 13():887125. PubMed ID: 35720301
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Advancements of in vitro transcribed mRNA (IVT mRNA) to enable translation into the clinics.
    Kang DD; Li H; Dong Y
    Adv Drug Deliv Rev; 2023 Aug; 199():114961. PubMed ID: 37321375
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Synthetic modified messenger RNA for therapeutic applications.
    Gao M; Zhang Q; Feng XH; Liu J
    Acta Biomater; 2021 Sep; 131():1-15. PubMed ID: 34133982
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Oral mRNA Vaccines Against Infectious Diseases- A Bacterial Perspective [Invited].
    Jawalagatti V; Kirthika P; Lee JH
    Front Immunol; 2022; 13():884862. PubMed ID: 35592330
    [TBL] [Abstract][Full Text] [Related]  

  • 11. COVID-19 mRNA vaccines: Platforms and current developments.
    Szabó GT; Mahiny AJ; Vlatkovic I
    Mol Ther; 2022 May; 30(5):1850-1868. PubMed ID: 35189345
    [TBL] [Abstract][Full Text] [Related]  

  • 12. mRNA vaccines: a new era in vaccine development.
    Chandra S; Wilson JC; Good D; Wei MQ
    Oncol Res; 2024; 32(10):1543-1564. PubMed ID: 39308511
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Advances in COVID-19 mRNA vaccine development.
    Fang E; Liu X; Li M; Zhang Z; Song L; Zhu B; Wu X; Liu J; Zhao D; Li Y
    Signal Transduct Target Ther; 2022 Mar; 7(1):94. PubMed ID: 35322018
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Vaccines on demand, part II: future reality.
    Geall AJ; Kis Z; Ulmer JB
    Expert Opin Drug Discov; 2023 Feb; 18(2):119-127. PubMed ID: 36384351
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cancer mRNA vaccines: clinical advances and future opportunities.
    Sayour EJ; Boczkowski D; Mitchell DA; Nair SK
    Nat Rev Clin Oncol; 2024 Jul; 21(7):489-500. PubMed ID: 38760500
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Messenger RNA Vaccine Technology: Success for SARS-CoV-2 and Prospects for an HIV-1 Vaccine.
    Files JK; Goepfert PA
    Top Antivir Med; 2024 Apr; 32(2):420-430. PubMed ID: 39141920
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of Immune Responses Elicited by SARS-CoV-2 mRNA and Recombinant Protein Vaccine Candidates.
    Wu Y; Zhang H; Meng L; Li F; Yu C
    Front Immunol; 2022; 13():906457. PubMed ID: 35663946
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The mRNA Vaccine Revolution: COVID-19 Has Launched the Future of Vaccinology.
    Ye Z; Harmon J; Ni W; Li Y; Wich D; Xu Q
    ACS Nano; 2023 Aug; 17(16):15231-15253. PubMed ID: 37535899
    [TBL] [Abstract][Full Text] [Related]  

  • 19. mRNA-based HIV-1 vaccines.
    Ahmed S; Herschhorn A
    Clin Microbiol Rev; 2024 Sep; 37(3):e0004124. PubMed ID: 39016564
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Making COVID-19 mRNA vaccines accessible: challenges resolved.
    Niazi SK
    Expert Rev Vaccines; 2022 Sep; 21(9):1163-1176. PubMed ID: 35695469
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.